Used in biomedical research to quantify Human Conjunctin-1 (Hapln1) levels in tissue extracts, serum, plasma, and other biological fluids. Enables researchers to study the role of Hapln1 in extracellular matrix stability, particularly in cartilage and connective tissues. Commonly applied in osteoarthritis and joint disease studies, where Hapln1 expression correlates with matrix integrity. Supports high-throughput screening in drug development and evaluation of therapeutic interventions targeting matrix degradation. Provides a reliable, sensitive, and specific method for detecting Hapln1 in clinical and preclinical research settings.